drugset / Trial / NCT06560528
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
NaSingle-groupOpen-labelTreatment
Summary
The efficacy and safety of combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2027-09-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |